Advertisement

Gastric Cancer

, Volume 20, Issue 2, pp 394–394 | Cite as

Nishi Memorial Award in Gastric Cancer

Announcement
  • 667 Downloads

The Japanese Gastric Cancer Association (JGCA) established the ‘‘Nishi Memorial Award in Gastric Cancer’’ to commend high-quality papers published in Gastric Cancer. In each volume of the journal, three articles are selected by the Editorial Committee, and the JGCA awards 100,000 Japanese yen to the first authors.

For Volume 19, the following articles were selected.

Exploratory phase II trial in a multicenter setting to evaluate the clinical value of a chemosensitivity test in patients with gastric cancer (JACCRO-GC 04, Kubota memorial trial).

“An in vitro chemosensitivity test, the collagen gel droplet-embedded drug sensitivity test (CD-DST), identified those who benefit from postoperative 5-fluorouracil-based adjuvant chemotherapy.”

Nobuhiko Tanigawa

 Gastric Cancer 2016; 19:350–360

Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).

“Weekly paclitaxel showed promising activity and lower incidences of neutropenia and diarrhea compared to best available 5-fluorouracil as second-line chemotherapy in patients with severe peritoneal metastases from gastric cancer.”

Tomohiro Nishina

 Gastric Cancer 2016; 19: 902–910

Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer: evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method.

EGFR GCN gain is a more accurate prognostic biomarker independent of other pathological findings, including EGFR overexpression or disease stage, for gastric cancer.”

Eiji Higaki

 Gastric Cancer 2016; 19: 63–73

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2017

Personalised recommendations